2016
Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers
DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, O’Malley S. Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2016, 84: 185-190. PMID: 26654213, PMCID: PMC4941818, DOI: 10.1037/ccp0000053.Peer-Reviewed Original ResearchConceptsPercent days abstinentFirst placebo-controlled trialPercent days heavy drinkingHeavy drinkingPlacebo-controlled trialLong-term outcomesHeavy drinking daysYoung adults ages 18Adults ages 18Naltrexone conditionActive medicationPlacebo groupPharmacotherapy trialsAdult heavy drinkersYoung adult heavy drinkersNonsignificant decreaseSignificant benefitsYear posttreatmentDays abstinentDrinking daysMost outcomesSingle interventionHeavy drinkersTreatment improvementAge 18
2011
A preliminary investigation of varenicline for heavy drinking smokers
Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011, 215: 655-663. PMID: 21221531, PMCID: PMC3645986, DOI: 10.1007/s00213-010-2160-9.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersActive medicationPretreatment groupAlcohol cravingHeavy drinkersOpen-label phaseSmoking cessation pharmacotherapyEffects of vareniclineHeavy drinking daysGreater reductionPlacebo leadVarenicline pretreatmentCessation counselingCessation pharmacotherapyAbstinence ratesCigarette smokingVareniclineSmoking changesDrinking daysPotential treatmentSmokingAlcohol dependenceEntire study periodSmokersHeavy drinking